Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]
Implants
Senseonics posts Q2 sales beat, submits 365-day CGM for CE mark
Senseonics (NYSE:SENS) shares dipped after hours today on first-quarter results that beat revenue projections on Wall Street. Shares of SENS fell 5% to 70¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $14.3 million. That equals 2¢ per share on sales of $6.26 million for the […]
Sequel Med Tech, Senseonics to integrate year-long CGM into automated insulin delivery system
Sequel Med Tech and Senseonics (NYSE:SENS) today announced a commercial development agreement to combine insulin delivery and glucose monitoring systems. The companies plan to integrate Sequel’s twiist automated insulin delivery system with the Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world’s […]
Data backs Boston Scientific drug-eluting stent
Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]
R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study
R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 […]
Glucotrack expects FDA IDE for implantable CBGM this year
Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption (IDE) for its long-term CBGM later this year. Rutherford, New Jersey-based Glucotrack develops a long-term implantable continuous blood glucose monitor (CBGM). The device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, […]
Vivani reports first human GLP-1 implant for weight loss in adults
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 clinical trial. This news comes just one day after Vivani announced plans to spin off its neurostimulation business to focus on its GLP-1 implants. The company also announced full enrollment in LIBERATE-1, achieved in just four weeks after the […]
Vivani to spin out neurostim business, focus on GLP-1 implant
Vivani Medical (Nasdaq:VANI) announced today that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic areas. Vivani aims to continue advancing its miniature GLP-1 therapeutic implants. The spin-off would enable Cortigent to continue […]
Senseonics expects to double global patient base in 2025, progresses with pump integration
Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of SENS went up nearly 7% to 93¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $15.5 million for the quarter. That equals losses 2¢ per […]
Senseonics inks diabetes management software deal for Eversense 365
Senseonics (NYSE:SENS) announced today that it integrated SweetSpot software with its Eversense 365 continuous glucose monitor (CGM) in the U.S. The software integration provides endocrinology practices that partner with SweetSpot the ability to seamlessly and regularly review data from patients using Eversense 365, the world’s first and only one-year CGM. Senseonics won FDA clearance for the Eversense […]
